PETALUMA -- Oculus Innovative Science, a health care products company, received patents in the U.S. for its Microcyn burn treatment product, and for its treatment of peritonitis, an infection that affects the lining of the abdomen and other organs.
The company (NASDAQ: OCLS, oculusis.com), based in Petaluma, manufactures and markets prescription and nonprescription products in 31 countries. Oculus products are used to treat patients with surgical and advanced wound management and are employed in dermatology, women's health and animal health.
According to a statement from Oculus, the company has 41 patents issued or allowed, and 92 pending applications.
On the news of the patent approvals, Oculus stock rose 0.44 percent Tuesday to close at $2.28 a share.
James Schutz is the Oculus CEO, appointed in 2013.
Sharon Barbari was appointed as a director earlier this year. She is executive vice president and CFO for Cytokinetics, Inc., a clinical-stage biopharmaceutical focused on the discovery and development of novel small molecule therapeutics.
